NEW YORK, Nov. 09, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased shares of ProNAi Therapeutics, Inc. (“ProNAi”) (NASDAQ:DNAI) between July 15, 2015 and June 6, 2016 (the “Class Period”). You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/pronai-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, ProNAi made materially false and misleading statements about the potential and efficacy of its drug product candidate PNT2258 in the company’s public filings, which caused ProNAi’s stock price to be artificially inflated throughout the Class Period, thus harming investors.
On June 6, 2016, ProNAi revealed that the Phase 2 clinical trials of PNT2258 failed to produce sufficient efficacy results to justify continued clinical development of the drug and, thus, ProNAi was suspending clinical development of PNT2258. Following this news, shares of ProNAi fell more than 67 percent.
If you suffered a loss in ProNAi you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 



